Loading...
Loading...
AVRO| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.0M |
| Gross Profit | 0.0M |
| Operating Expense | 27.8M |
| Operating I/L | -27.8M |
| Other Income/Expense | -0.3M |
| Interest Income | 0.0M |
| Pretax | -28.1M |
| Income Tax Expense | 0.3M |
| Net Income/Loss | -28.3M |
AVROBIO, Inc. is a clinical-stage gene therapy company specializing in ex vivo lentiviral-based gene therapies for rare diseases. The company's gene therapies utilize hematopoietic stem cells collected from patients and modified with a lentiviral vector to insert functional copies of the defective gene in the target disease. Its product portfolio includes AVR-RD-01 for Fabry disease, AVR-RD-02 in phase 1/2 trial for type 1 Gaucher disease, AVR-RD-03 for Pompe disease, AVR-RD-04 for cystinosis, AVR-RD-05 for Hunter syndrome, and AVR-RD-06 in preclinical stage for Gaucher disease type 3.
